GlobeNewswire Inc.··NaNeurocrine Advances Nxera's Schizophrenia Drug into Phase 2 with First Patient Dosed
Neurocrine Biosciences doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggering $22.5M milestone payment to partner Nxera Pharma.
NBIXPhase 2 clinical trialdrug discovery